Explainer-Who is eligible for the new FDA-approved Alzheimer’s drug?
By Deena Beasley The U.S. Food and Drug Administration on Thursday granted standard approval to Eisai and Biogen’s Leqembi for…
Business
Marketmind: Markets buckle under US rates, China blues
By Jamie McGeever (Reuters) – A look at the day ahead in Asian markets from Jamie McGeever, financial markets columnist….
Meta takes aim at Twitter with Threads app, millions join
(Corrects grammar in first paragraph) By Katie Paul NEW YORK (Reuters) -Meta Platforms on Wednesday launched a direct challenge to…
Analysis-Will abandoning American help JetBlue’s Spirit merger? Not by much
By Rajesh Kumar Singh and Diane Bartz CHICAGO/WASHINGTON (Reuters) – JetBlue Airways’ decision to abandon its alliance with American Airlines…
Rivian must face lawsuit claiming it defrauded IPO investors over vehicle prices
By Jonathan Stempel (Reuters) – A federal judge said Rivian Automotive must face a lawsuit claiming it defrauded shareholders during…
Bausch + Lomb expands eye-care portfolio with J&J’s Blink
(Reuters) – Bausch + Lomb acquired Johnson & Johnson’s eye and contact lens drops brand Blink for $106.5 million, marking…
Deadline set by crypto’s Winklevoss looms for Genesis repayment deal
By Hannah Lang (Reuters) – Time is running out for Digital Currency Group to agree on a deal to restructure…
US agency seeks updated responses from Tesla in Autopilot probe
By David Shepardson WASHINGTON (Reuters) -U.S. auto safety regulators said on Thursday they are seeking updated responses and current data…
AbbVie trims full-year profit forecast on higher R&D expenses
(Reuters) -AbbVie Inc cut its full-year profit forecast on Thursday, citing $280 million in milestone and in-process research and development…
Nikola pushes shareholder meet again as it seeks nod for key proposal
(Reuters) – Electric-truck maker Nikola on Thursday adjourned its annual shareholder meeting for the second time this year, as it…